Distinguished in Enlarged Liver

Dr. Parvez S. Mantry

Gastroenterology | Hepatology
Baylor Scott & White Health
MedHealth DBA Methodist Transplant Specialists
1411 N Beckley Ave Pavilion III, Ste 268, 
Dallas, TX 
Offers Telehealth
Distinguished in Enlarged Liver
Baylor Scott & White Health
MedHealth DBA Methodist Transplant Specialists
1411 N Beckley Ave Pavilion III, Ste 268, 
Dallas, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Parvez Mantry is a Hepatologist and a Gastroenterologist in Dallas, Texas. Dr. Mantry is rated as a Distinguished provider by MediFind in the treatment of Enlarged Liver. His top areas of expertise are Nonalcoholic Steatohepatitis (NASH), Liver Failure, Hepatitis, Liver Transplant, and Endoscopy.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Bombay
Specialties
Gastroenterology
Hepatology
Licenses
Internal Medicine in TX
Hospital Affiliations
Methodist Dallas Medical Center
Methodist Richardson Medical Center
Bsa Hospital
Methodist Charlton Medical Center
Navarro Regional Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
El Paso Health
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 21 Less Insurance Carriers -

Locations

MedHealth DBA Methodist Transplant Specialists
1411 N Beckley Ave Pavilion III, Ste 268, Dallas, TX 75203
Call: 972-449-0540
Other Locations
MedHealth DBA Methodist Transplant Specialists
Lubbock, TX 79401
Call: 214-947-4400
MedHealth DBA Methodist Transplant Specialists
5300 W Plano Pkwy Ste 300, Plano, TX 75093
Call: 214-947-4400

Additional Areas of Focus

Dr. Mantry has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Terminated
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
Enrollment Status: Active_not_recruiting
Publish Date: November 20, 2025
Intervention Type: Drug
Study Drug: Volixibat
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
Enrollment Status: Active_not_recruiting
Publish Date: November 19, 2025
Intervention Type: Drug
Study Drug: HM15211
Study Phase: Phase 2
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
The HepQuant SHUNT Liver Diagnostic Kit for Likelihood of Large Esophageal Varices: The SHUNT-V Study
Enrollment Status: Completed
Publish Date: April 11, 2025
Intervention Type: Combination product
Study Phase: Not Applicable
A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
A Prospective, Multicenter, Open-label Single Arm Study Evaluating the Safety & Efficacy of Selective Internal Radiation Therapy Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients
Enrollment Status: Active_not_recruiting
Publish Date: February 05, 2025
Intervention Type: Device
Study Phase: Not Applicable
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy
Enrollment Status: Terminated
Publish Date: January 09, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer
Enrollment Status: Terminated
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drugs: Bintrafusp Alfa, Gemcitabine, Cisplatin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
A Phase 4, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Pharmacokinetics and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis and Moderate to Severe Hepatic Impairment
Enrollment Status: Terminated
Publish Date: September 06, 2022
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 4
A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
A Humanitarian Device Exemption Treatment Protocol of TheraSphere for Treatment of Unresectable Primary or Unresectable Secondary Liver Cancer
Enrollment Status: Completed
Publish Date: November 11, 2021
Intervention Type: Device
Study Phase: Not Applicable
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Evaluation of HepQuant SHUNT to Assess Liver Disease; Substudy Within GS-US-416-2124
Enrollment Status: Withdrawn
Publish Date: August 30, 2021
Intervention Type: Drug, Device
Study Phase: Early Phase 1
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
The HepQuant SHUNT Test for Monitoring Liver Disease and Treatment Effects by Measuring Liver Function and Physiology
Enrollment Status: Terminated
Publish Date: August 09, 2021
Intervention Type: Combination product
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 12-Month, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of Three Dose Levels of MSDC-0602K in Patients With NASH (EMMINENCE™)
Enrollment Status: Completed
Publish Date: September 16, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis (AIH) Patients Who Are Refractory or Intolerant to Current Therapies
Enrollment Status: Completed
Publish Date: July 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects With Decompensated Non-Alcoholic Steatohepatitis (NASH) Cirrhosis
Enrollment Status: Unknown
Publish Date: March 19, 2019
Intervention Type: Drug
Study Drug: Emricasan
Study Phase: Phase 2
View 16 Less Clinical Trials

46 Total Publications

Nebokitug, an anti-CCL24 monoclonal antibody, in patients with primary sclerosing cholangitis: A phase 2 study.
Nebokitug, an anti-CCL24 monoclonal antibody, in patients with primary sclerosing cholangitis: A phase 2 study.
Journal: The American journal of gastroenterology
Published: July 28, 2025
View All 46 Publications
Similar Doctors
Distinguished in Enlarged Liver
Dr. Jeffrey Weinstein
Hepatology
Distinguished in Enlarged Liver
Dr. Jeffrey Weinstein
Hepatology

Medhealth

1411 N Beckley Ave, Suite 268, 
Dallas, TX 
 (1.5 miles away)
214-947-4400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jeffrey Weinstein is a Hepatologist in Dallas, Texas. Dr. Weinstein is rated as a Distinguished provider by MediFind in the treatment of Enlarged Liver. His top areas of expertise are Congenital Hepatic Fibrosis, Hepatitis, Visceromegaly, Enlarged Liver, and Liver Transplant.

Distinguished in Enlarged Liver
Dr. Apurva Modi
Hepatology
Distinguished in Enlarged Liver
Dr. Apurva Modi
Hepatology

Healthtexas Provider Network

5408 Colleyville Blvd, 
Colleyville, TX 
 (22.5 miles away)
817-498-9920
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Apurva Modi is a Hepatologist in Colleyville, Texas. Dr. Modi is rated as a Distinguished provider by MediFind in the treatment of Enlarged Liver. His top areas of expertise are Hepatitis, Hepatitis C, Visceromegaly, Alcoholic Cirrhosis, and Endoscopy.

Distinguished in Enlarged Liver
Dr. Manjushree Gautam
Hepatology
Distinguished in Enlarged Liver
Dr. Manjushree Gautam
Hepatology

Healthtexas Provider Network

1400 8th Ave, 
Fort Worth, TX 
 (31.6 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Manjushree Gautam is a Hepatologist in Fort Worth, Texas. Dr. Gautam is rated as a Distinguished provider by MediFind in the treatment of Enlarged Liver. Her top areas of expertise are Hepatitis, Visceromegaly, Enlarged Liver, Liver Failure, and Endoscopy.

VIEW MORE ENLARGED LIVER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Mantry's expertise for a condition
ConditionClose
  • Elite
  • Hepatitis
    Dr. Mantry is
    Elite
    . Learn about Hepatitis.
    See more Hepatitis experts
  • Liver Failure
    Dr. Mantry is
    Elite
    . Learn about Liver Failure.
    See more Liver Failure experts
  • Nonalcoholic Steatohepatitis (NASH)
    Dr. Mantry is
    Elite
    . Learn about Nonalcoholic Steatohepatitis (NASH).
    See more Nonalcoholic Steatohepatitis (NASH) experts
  • Distinguished
  • Ascites
    Dr. Mantry is
    Distinguished
    . Learn about Ascites.
    See more Ascites experts
  • Bile Duct Obstruction
    Dr. Mantry is
    Distinguished
    . Learn about Bile Duct Obstruction.
    See more Bile Duct Obstruction experts
  • Cholangiocarcinoma (Bile Duct Cancer)
    Dr. Mantry is
    Distinguished
    . Learn about Cholangiocarcinoma (Bile Duct Cancer).
    See more Cholangiocarcinoma (Bile Duct Cancer) experts
  • Cholangitis
    Dr. Mantry is
    Distinguished
    . Learn about Cholangitis.
    See more Cholangitis experts
  • Cholestasis
    Dr. Mantry is
    Distinguished
    . Learn about Cholestasis.
    See more Cholestasis experts
  • Cirrhosis
    Dr. Mantry is
    Distinguished
    . Learn about Cirrhosis.
    See more Cirrhosis experts
View All 13 Distinguished Conditions
  • Advanced
  • Alcoholic Cirrhosis
    Dr. Mantry is
    Advanced
    . Learn about Alcoholic Cirrhosis.
    See more Alcoholic Cirrhosis experts
  • Autoimmune Hepatitis
    Dr. Mantry is
    Advanced
    . Learn about Autoimmune Hepatitis.
    See more Autoimmune Hepatitis experts
  • Bile Duct Stricture
    Dr. Mantry is
    Advanced
    . Learn about Bile Duct Stricture.
    See more Bile Duct Stricture experts
  • Esophageal Varices
    Dr. Mantry is
    Advanced
    . Learn about Esophageal Varices.
    See more Esophageal Varices experts
  • Liver Cancer
    Dr. Mantry is
    Advanced
    . Learn about Liver Cancer.
    See more Liver Cancer experts
  • Liver Transplant
    Dr. Mantry is
    Advanced
    . Learn about Liver Transplant.
    See more Liver Transplant experts
View All 10 Advanced Conditions
  • Experienced
  • Anemia
    Dr. Mantry is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Banti's Syndrome
    Dr. Mantry is
    Experienced
    . Learn about Banti's Syndrome.
    See more Banti's Syndrome experts
  • Choledocholithiasis
    Dr. Mantry is
    Experienced
    . Learn about Choledocholithiasis.
    See more Choledocholithiasis experts
  • Chronic Erosive Gastritis
    Dr. Mantry is
    Experienced
    . Learn about Chronic Erosive Gastritis.
    See more Chronic Erosive Gastritis experts
  • Congenital Hepatic Fibrosis
    Dr. Mantry is
    Experienced
    . Learn about Congenital Hepatic Fibrosis.
    See more Congenital Hepatic Fibrosis experts
  • End-Stage Renal Disease (ESRD)
    Dr. Mantry is
    Experienced
    . Learn about End-Stage Renal Disease (ESRD).
    See more End-Stage Renal Disease (ESRD) experts
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.